The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Exercise is Good and Media Coverage of Exercise is Bad
July 13th 2015The reaction to an editorial claiming that exercise alone will not help patients lose weight is illustrative of the biases held by certain groups and underscores the need for greater education and awareness of the science of weight loss for patients and clinicians.
Diabetes Risk is Reduced by Egg Consumption
July 13th 2015A recent study out of Finland found that men who ate chicken eggs on a regular basis had a lower risk of developing type 2 diabetes mellitus. Like a number of other recent studies this article stands in contrast to what was once the conventional wisdom: that eating foods high in cholesterol would increase your risk of heart disease and its risk factors.
Post-Marketing Study Shows Rivaroxaban Safe for Use in Elderly Patients with Atrial Fibrillation
A multi-year study of rivaroxaban in patients with non-valvular atrial fibrillation demonstrated that the drug is about as safe in real-world usage as it was in phase 3 trials.
PCSK9 Inhibitors: Newer Does Not Always Mean Better
July 1st 2015With much fanfare earlier this month, the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration endorsed approval of 2 new highly-anticipated, injectable agents for lowering cholesterol, alirocumab and evolocumab. Although the FDA is not obliged to follow these recommendations, it is a only a matter of time before these two proprotein convertase subtilisin kexin 9 inhibitors will be available by prescription in the United States.
How Would You Manage This Man With Non-alcoholic Fatty Liver Disease
July 1st 2015You see a 48-year-old white man for his annual examination. He is in good health with no major medical problems and an unremarkable medical history. He states he regularly drinks one or two beers a day on the weekend but not usually on weekdays. He denies blood transfusions, tattoos or intravenous drugs. His father had diabetes. Physical examination is notable for the patient being mildly obese with a body mass index of 32.
Q&A with Valder R. Arruda, MD, PhD
Dr. Arruda is a hematology researcher at The Children's Hospital of Philadelphia and an associate professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. His laboratory focuses on gene-based strategies for the treatment of bleeding and thrombotic diseases.
Proton Pump Inhibitors Increase CHD Risk
July 1st 2015There is consistent observational data that identifies concomitant use of proton pump inhibitors for gastroesophageal reflux disease and clopidogrel following acute coronary syndrome increases the risk of recurrent cardiovascular events. While a variety of theories exist (lower pH alters absorption, etc.), no clear factor has been identified.
How Accurate are Cardiac Risk Calculators?
July 1st 2015This prospective epidemiological study compares the capabilities of the new 2013 American Heart Association and American College of Cardiology ASCVD risk calculator against several alternative cardiovascular risk calculators and explores the potential effect of preventive therapy on risk overestimation in the AHA-ACC-ASCVD model.
Primary Care: Gold at End of Rocky Road?
As the US population ages, better primary care is essential to keeping costs down. But so far, the new focus on that specialty has not resulted in adequate reimbursement, said Brent Egan, MD, speaking June 27 at a meeting of primary care physicians in Charleston, SC. He believes that will change.
Despite Steady Increase in Chemoprophylaxis Use, Annual VTE Incidence Low
Colorectal surgery is often performed for inflammatory disease or malignancy-known risk factors for venous thromboembolism (VTE). Although a patient safety priority, comprehensive recommendations for these VTE patients are lacking. Most patients receive perioperative and in-hospital VTE chemoprophylaxis, but extended prophylaxis rates lag.